Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Rating) major shareholder Tpg Gp A, Llc sold 436,431 shares of Trevi Therapeutics stock in a transaction on Friday, July 1st. The shares were sold at an average price of $2.86, for a total value of $1,248,192.66. Following the transaction, the insider now directly owns 3,888,452 shares of the company's stock, valued at $11,120,972.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
特雷维治疗公司(纳斯达克代码：TRVI-GET评级)的大股东TPG GP A，LLC在7月1日(星期五)的一笔交易中出售了436,431股特雷维治疗公司的股票。这些股票的平均价格为2.86美元，总价值为1,248,192.66美元。交易完成后，这位内部人士现在直接持有该公司3888,452股股票，价值11,120,972.72美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过美国证券交易委员会网站访问。持有公司10%或以上股份的大股东必须披露他们与美国证券交易委员会的交易。
Tpg Gp A, Llc also recently made the following trade(s):
TPG GP A，LLC最近还进行了以下交易：
- On Tuesday, July 5th, Tpg Gp A, Llc sold 63,569 shares of Trevi Therapeutics stock. The shares were sold at an average price of $3.11, for a total value of $197,699.59.
- On Wednesday, June 29th, Tpg Gp A, Llc sold 46,128 shares of Trevi Therapeutics stock. The shares were sold at an average price of $2.74, for a total value of $126,390.72.
- On Monday, May 2nd, Tpg Gp A, Llc sold 600 shares of Trevi Therapeutics stock. The shares were sold at an average price of $2.70, for a total value of $1,620.00.
- On Thursday, April 28th, Tpg Gp A, Llc sold 7,271 shares of Trevi Therapeutics stock. The shares were sold at an average price of $2.77, for a total value of $20,140.67.
- 7月5日，星期二，TPG GP A，LLC出售了63,569股Trevi治疗公司的股票。这些股票的平均价格为3.11美元，总价值为197699.59美元。
- 6月29日，星期三，TPG GP A，LLC出售了46,128股Trevi Treeutics股票。这些股票的平均价格为2.74美元，总价值为126,390.72美元。
- 5月2日，星期一，TPG GP A，LLC出售了600股Trevi治疗公司的股票。这些股票的平均价格为2.70美元，总价值为1,620.00美元。
- 4月28日，星期四，TPG GP A，LLC出售了7271股Trevi治疗公司的股票。这些股票的平均价格为2.77美元，总价值为20,140.67美元。
Shares of NASDAQ:TRVI opened at $3.79 on Friday. The stock has a market capitalization of $146.64 million, a P/E ratio of -2.81 and a beta of 0.18. Trevi Therapeutics, Inc. has a 1-year low of $0.46 and a 1-year high of $3.86. The company has a current ratio of 2.32, a quick ratio of 2.32 and a debt-to-equity ratio of 0.67. The business has a 50-day moving average price of $2.40 and a two-hundred day moving average price of $1.74.
A number of research analysts recently issued reports on TRVI shares. Oppenheimer lifted their price target on Trevi Therapeutics to $12.00 in a report on Monday. Needham & Company LLC lifted their price target on Trevi Therapeutics from $8.00 to $10.00 and gave the company a "buy" rating in a report on Wednesday, June 29th. Finally, Aegis assumed coverage on Trevi Therapeutics in a report on Tuesday, March 29th. They issued a "buy" rating and a $10.00 price target for the company.
Several institutional investors have recently bought and sold shares of TRVI. Commonwealth Equity Services LLC acquired a new position in shares of Trevi Therapeutics during the 1st quarter worth about $33,000. WealthTrust Axiom LLC grew its position in shares of Trevi Therapeutics by 245.6% during the 1st quarter. WealthTrust Axiom LLC now owns 98,500 shares of the company's stock worth $216,000 after buying an additional 70,000 shares during the period. MAI Capital Management acquired a new position in shares of Trevi Therapeutics during the 1st quarter worth about $3,391,000. Vanguard Group Inc. grew its position in shares of Trevi Therapeutics by 7.6% during the 1st quarter. Vanguard Group Inc. now owns 152,831 shares of the company's stock worth $336,000 after buying an additional 10,780 shares during the period. Finally, State Street Corp acquired a new position in shares of Trevi Therapeutics during the 1st quarter worth about $81,000. Institutional investors own 75.34% of the company's stock.
几家机构投资者最近买卖了TRVI的股票。英联邦股权服务有限责任公司在第一季度收购了Trevi治疗公司的新股份，价值约33,000美元。第一季度，WealthTrust Axiom LLC在特雷维治疗公司的股票持有量增加了245.6%。WealthTrust Axiom LLC现在拥有98,500股该公司的股票，价值21.6万美元，在此期间又购买了70,000股。Mai资本管理公司在第一季度收购了Trevi治疗公司的新股票，价值约3391,000美元。第一季度，先锋集团在Trevi治疗公司的股票持有量增加了7.6%。先锋集团现在持有152,831股该公司股票，价值336,000美元，在此期间又购买了10,780股。最后，道富银行在第一季度收购了Trevi治疗公司股票的新头寸，价值约81,000美元。机构投资者持有该公司75.34%的股票。
About Trevi Therapeutics (Get Rating)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.
- Get a free copy of the StockNews.com research report on Trevi Therapeutics (TRVI)
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Credo Technology Stock is Rebounding
- Investing In Preferred Stock vs. Common Stock
- Profiting From 52 Week Low Stocks
- Three Cheap Stocks The Insiders Are Buying
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.